Micafungin CAS 235114-32-6
Introduction：Basic information about Micafungin CAS 235114-32-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Micafungin Basic informationDescription References
| Product Name: | Micafungin |
| Synonyms: | MICAFUNGIN;Micfungin;PubChem ID: 11804463;PubChem ID: 122130057;PubChem ID: 477468;PubChem ID: 78357831;PubChem ID: 3081921;Micafungin (Acid) |
| CAS: | 235114-32-6 |
| MF: | C56H71N9O23S |
| MW: | 1270.28 |
| EINECS: | 1806241-263-5 |
| Product Categories: | API;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics;Heterocycles;Antifungals;235114-32-6 |
| Mol File: | 235114-32-6.mol |
Micafungin Chemical Properties
| Melting point | >198oC (dec.) |
| density | 1.62±0.1 g/cm3(Predicted) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Very Slightly, Heated) |
| pka | -4.46±0.18(Predicted) |
| form | Solid |
| color | White to Off-White |
| Stability: | Hygroscopic |
| InChIKey | PIEUQSKUWLMALL-VUVMFQHDNA-N |
Safety Information
| Description | Micafungin (trade name Mycamine) is a kind of echinocandin antifungal drug. Its mechanism of action is through inhibiting the synthesis of beta-1, 3-glucan, which is an essential component of fungal cell walls, but not presented in mammalian cells. It works through inhibiting the beta-1,3-D glucan synthase. It can be used for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, abscesses and esophageal candidiasis. It is fungicidal against some candida, but fungistatic against Apergillus. It is also used in combinations with many other drugs such as the HIV protease inhibitor ritonavir as well as the transplant medications cyclosporine and tacrolimus. |
| References | https://www.drugbank.ca/drugs/DB01141 https://en.wikipedia.org/wiki/Micafungin |
| Description | Micafungin, the secondmember of the echinocandinclass of antifungal agents waslaunched in Japan forthe parenteral treatment ofvarious fungal infections causedby Aspergillus and Candida spp.such as fungaemia andrespiratory and gastrointestinalmycoses. This water-solublesemisynthetic cyclic lipopeptide is synthesized by acylation with (5-(4-pentyloxyphenyl)isoxazol-3-yl)benzoate of the cyclic peptide nucleus (FR-179642).obtained by enzymatic cleavage of the naturally occurring echinocandin FR-901379,derived from the fungus Coleophoma empedri Micafungin acts by inhibiting the synthesisof 1,3-beta-glucan, an essential polysaccharide of the cell wall of many pathogenic fungi.Micafungin has a marked fungicidal effect on almost all species of Candida, includingfluconazole-resistant spp. C. albicans, C. glabrata, C. Krusei, C. parapsilosis and C.tropicalis and a fungistatic effect on a range of Aspergillus species including A. flaws, A.fumigates and A. terreus. Like caspofungin, micafungin is inactive against Cryptococcusneoformans, and the emerging pathogen Trichosporon cutaneum and Fusarium solani.Micafungin has proved highly effective in mouse models of Cancfidiasis and Aspergillusinfections (including those using an amphotericin B- and itraconazole-resistant isolate of A.fumigatus). In phase I studies, micafungin had linear pharmacokinetics with an eliminationhalf-life ranging from 11.7 to 15.2 h after injection and was well tolerated. |
| Originator | Fujisawa (Japan) |
| Uses | Micafungin is an antifungal drug that inhibits the production of β-1,3-glucan, an essential component of fungal cell walls. |
| Uses | An echinocandin antifungal drug which inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, and represent a valuable treatment option for fungal infections. |
| Uses | Micafungin is a semi-synthetic cyclic lipopeptide belonging to the echinocandin class that was reported in 1999 from Fujisawa in Japan. Unlike other marketed semi-synthetic derivatives in this class, micafungin is not derived from echinocandin but rather from FR901379 which contains a phenolic sulphate to enhance aqueous solubility, a serious limitation in the class. Micafungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi and is extensively referenced in the literature with over 700 citations. |
| Definition | ChEBI: A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasve candidiasis, and of aspergillosis in patients who are intolerant of other therapy. |
| Brand name | Mycamine(Astellas);Funguard. |
| Antimicrobial activity | It is active against Aspergillus spp., Candida spp. and the cystform of Pn. jirovecii. Resistance has rarely been reported. |
| Pharmaceutical Applications | A semisynthetic lipopeptide derived from a fermentationproduct of Coleophoma empetri. Formulated as the monosodiumsalt for intravenous infusion. |
| Pharmacokinetics | Cmax 50 mg 1-h infusion: c. 5 mg/L 1 h post infusion Plasma half-life: 11–15 h Volume of distribution: 0.4 L/kg Plasma protein binding: 99% Blood concentrations increase in proportion to dosage. Unlike anidulafungin and caspofungin, a loading dose is not required. Distribution The drug is widely distributed, the highest concentrations being found in the liver. Levels in the CSF and urine are negligible. Metabolism and excretion It is metabolized by the liver and the three inactive metabolites are excreted in the feces (70%). Less than 1% of a dose is eliminated as unchanged drug in the urine. No dosage adjustment is required in patients with severe renal impairment or mild to moderate hepatic impairment. The effect of severe hepatic impairment on micafungin pharmacokinetics has not been studied. Micafungin is not cleared by hemodialysis. |
| Clinical Use | Candidemia and certain invasive forms of candidosis Esophageal candidosis Prophylaxis of Candida infections in hematopoietic stem cell transplant(HSCT) recipients |
| Side effects | Occasional histamine-mediated infusion-related reactions,injection site reactions and transient abnormalities of liverenzymes have been reported. Isolated cases of significanthepatic or renal dysfunction, hepatitis, or liver or renal failurehave also been described. |
| Drug interactions | Potentially hazardous interactions with other drugs Ciclosporin: possibly increases ciclosporin concentration. Sirolimus: increases sirolimus concentration. |
| Metabolism | Metabolised in the liver by arylsulfatase to its catechol form and further metabolised to the methoxy form by catechol-O-methyltransferase. Some hydroxylation to micafungin via cytochrome P450 isoenzymes also occurs. Exposure to these metabolites is low and metabolites do not contribute to the overall efficacy of micafungin.After 28 days about 71% of a dose is recovered in the faeces and 12% in the urine. |
Micafungin Preparation Products And Raw materials
